1.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20040249, NCT00115765
|
|
2.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N05C4, N05C4, NCCTG N05C4, NCT00362986
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20050181, NCT00339183
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20050203, NCT00364013
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20050251, SPECTRUM, NCT00460265
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: HN6, CAN-NCIC-HN6, CDR0000630159, NCT00820248
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 82
Sponsor: Other
Protocol IDs: Pro00002207, SPS 151596, NCT00578071
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20060332, NCT00630786
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 20060447, NCT00788957
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CSTI571BUS278T, NCT00867334
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069368, UCLA-0112063, IMMUNEX-054-0005, NCI-G02-2073, NCT00039273
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0203073, IMMUNEX-054.0009, NCI-G02-2115, NCT00047151
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000269889, P30CA016042, UCLA-0206074, ABX-0301, NCT00054574
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0304051, IMMUNEX-054.0004, ABX-0304, AMGEN-20025404, NCT00034346
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ABX-0310, ABX-EGF, NCT00061126
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0308088, IMMUNEX-054.0008, AMGEN-20025408, ABX-0308, NCT00079209
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0402029-01, AMGEN-2003167, NCT00083616
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20050216, NCT00327119
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 20060277, NCT00411450
|
|
20.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Closed
Age: 18 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20050184, NCT00332163
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20060141, NCT00418938
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20062088, NCT00446446
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: TTD-06-04, NCT00475293
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20062080, NCT00500760
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20060314, EUDRACT Number 2006-006739-36, NCT00508404
|
Mobile | Español
